chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram, Arthralgia, Back pain, Chest pain, Chills
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Dyspnoea, Ejection fraction, Ejection fraction decreased, Electrocardiogram, Headache
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Myocarditis, Pain, Pain in extremity, Pyrexia, SARS-CoV-2 test
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Troponin, Troponin increased, Ultrasound scan, Vital signs measurement
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Angiogram normal, Cardiac imaging procedure abnormal, Chest pain, Dyspnoea, Echocardiogram
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Electrocardiogram abnormal, Myocarditis, Troponin increased, Ultrasound scan abnormal
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Myocarditis
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 39.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Ejection fraction, Myocarditis, Troponin I
Clinical narrative: Myocarditis; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; My heart ejection fraction was reduced to 35-40 percent and had a troponin level that spiked to 11; having pain in my shoulder and left arm; having pain in my shoulder and left arm; body aches; headache; fever; chills; shortness of breath; chest pains; shooting pain in back; This is a spontaneous report from a contactable consumer (patient). A 39-year-old male patient received bnt162b2 (Pfizer BioNTech Covid 19), dose 2 via an unspecified route of administration, administered in right arm on 11Apr2021 11:00 (Lot Number: EW0153) as single dose for COVID-19 immunisation. The patient has no known allergies and has no other medical history. Concomitant medications were not reported. The patient had no other vaccine in four weeks and had no other medications in two weeks. The patient previously received 1st dose of bnt162b2 (Pfizer BioNTech Covid 19, lot number EL9264) on 21Mar2021 03:00 PM in the right arm for COVID-19 immunisation. The patient was not diagnosed with covid prior vaccination. It was confirmed that after receiving the second dose, the patient experienced chills, fever, headache, body aches. Those symptoms went away about 24-36 hours later. The patient started experiencing shortness of breath and chest pains. The pain increased over time and started having pain in shoulder and left arm. Fever began off and on. Experienced chest pains, when tried to lie down, had shooting pain in back. The patient went to the emergency room and was subsequently admitted to the hospital where he was diagnosed with myocarditis. Heart ejection fraction was in 30s (reduced to 35-40 percent) and had a troponin level that spiked to 11. Angiogram did not indicate tears or blockages. Vital checks good as of 15Apr2021. Initial COVID-19 test on 14Apr2021 (unsure of type) was positive; plan to retest today (15Apr2021) for confirmation. It was also reported on 23Apr2021 that Nasal Swab on 14Apr2021 was negative. Onset of events reported as 13Apr2021 07:30 PM. The patient underwent lab tests and procedures which included angiogram: did not indicate tears or blockages on 13Apr2021, electrocardiogram (EKG): unknown result on unspecified date, heart function/heart ejection fraction: 30s on 13Apr2021 (reduced to 35-40 percent), COVID-19 test (unsure of type): positive on 14Apr2021, vital checks: good on 15Apr2021, nasal swab COVID-19 test: negative on 14Apr2021, troponin: spiked to 11 on 13Apr2021, ultrasound: unknown result on unspecified date. Events resulted in emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event). The patient was hospitalized for 2 days for the events. The patient received treatment for events. Outcome of events was reported as recovering.
Age: 44.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Computerised tomogram, Splenic infarction
Clinical narrative: Splenic intarct 44 yo male with CAD, GOUT, Dylipidemia, p/w abdomen pain about one week after second dose of Covid-19 vaccine. CT scan w/ thickening of celiac artery and its proximal branches, including the proximal splenic artery with vasculitis.
Age: 44.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Abdominal pain, Coeliac artery stenosis, Computerised tomogram thorax abnormal, Coronary artery disease, Dyslipidaemia
Clinical narrative: Splenic intarct 44 yo male with CAD, GOUT, Dylipidemia, p/w abdomen pain about one week after second dose of Covid-19 vaccine. CT scan w/ thickening of celiac artery and its proximal branches, including the proximal splenic artery with vasculitis.
Age: 44.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Gout, Splenic artery stenosis, Splenic infarction, Vasculitis
Clinical narrative: Splenic intarct 44 yo male with CAD, GOUT, Dylipidemia, p/w abdomen pain about one week after second dose of Covid-19 vaccine. CT scan w/ thickening of celiac artery and its proximal branches, including the proximal splenic artery with vasculitis.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Migraine, Visual impairment
Clinical narrative: pt developed visual changes and severe hypertension starting about 5-6 days following vaccine.  presented to PCP after 2 weeks of continued symptoms.  Sent to ED for evaluation.  CTA head showed clot in the distal M1 branch of the left MCA.  due to the amount of time she had had symptoms, no intervention was initiated.   Admitted to the hospital overnight for further testing.  discharged the next day on antihypertensives.  continues to have severe hypertension
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Angiogram cerebral abnormal, Cerebral artery thrombosis, Computerised tomogram head abnormal, Electroencephalogram normal, Full blood count normal
Clinical narrative: pt developed visual changes and severe hypertension starting about 5-6 days following vaccine.  presented to PCP after 2 weeks of continued symptoms.  Sent to ED for evaluation.  CTA head showed clot in the distal M1 branch of the left MCA.  due to the amount of time she had had symptoms, no intervention was initiated.   Admitted to the hospital overnight for further testing.  discharged the next day on antihypertensives.  continues to have severe hypertension
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypertension, Magnetic resonance imaging head normal, Venogram normal, Visual impairment
Clinical narrative: pt developed visual changes and severe hypertension starting about 5-6 days following vaccine.  presented to PCP after 2 weeks of continued symptoms.  Sent to ED for evaluation.  CTA head showed clot in the distal M1 branch of the left MCA.  due to the amount of time she had had symptoms, no intervention was initiated.   Admitted to the hospital overnight for further testing.  discharged the next day on antihypertensives.  continues to have severe hypertension
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Angiogram pulmonary normal, Cardio-respiratory arrest, Chest pain, Death, Fibrin D dimer increased
Clinical narrative: PATIENT DIED
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Resuscitation
Clinical narrative: PATIENT DIED
Age: 73.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Death
Clinical narrative: PATIENT DIED
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Chills, Headache, Nausea, Vomiting
Clinical narrative: 4-13-21 upon waking up, woke up migraines. took her migraine medication and migraine resolved. phlegm, fatigue, chills. 4-22-21 started numbness to lips and fingers with cold sensation. Reports no changes to color of skin so unlikely there is noticeable perfusion changes however advised to get seen at a HCF for this.  spoke with pcp for the migraine.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Condition aggravated, Fatigue, Feeling cold, Hypoaesthesia
Clinical narrative: 4-13-21 upon waking up, woke up migraines. took her migraine medication and migraine resolved. phlegm, fatigue, chills. 4-22-21 started numbness to lips and fingers with cold sensation. Reports no changes to color of skin so unlikely there is noticeable perfusion changes however advised to get seen at a HCF for this.  spoke with pcp for the migraine.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia oral, Migraine, Productive cough
Clinical narrative: 4-13-21 upon waking up, woke up migraines. took her migraine medication and migraine resolved. phlegm, fatigue, chills. 4-22-21 started numbness to lips and fingers with cold sensation. Reports no changes to color of skin so unlikely there is noticeable perfusion changes however advised to get seen at a HCF for this.  spoke with pcp for the migraine.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood magnesium, Differential white blood cell count, Dizziness, Electrocardiogram, Full blood count
Clinical narrative: BENIGN PAROXYSMAL POSITIONAL VERTIGO; OUT OF CHARACTER DECISION MAKING; FAINTNESS; FLU LIKE SYMPTOMS; This spontaneous report received from a patient concerned a 27 year old female. The patient's height, and weight were not reported. The patient never experienced a reaction to any other vaccine in past. the patient had no past medical issues. The patient had never experienced vertigo or dizziness and had no recent changes to diet, activities, or lifestyle. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on left arm on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021 (upon receiving the vaccine), the patient experienced flu-like symptoms, a high fever and body aches for the first 24 hours. On 13-APR-2021, the patient began to experience severe dizziness, vertigo, faintness, mild headaches, blurred vision, and out of character decision making. On 16-APR-2021 at 15:15, the patient was hospitalized for severe dizziness and blurred vision where he had blood human chorionic gonadotrophin, complete blood count (CBC), comprehensive metabolic panel, electrocardiogram, blood magnesium level and urinalysis (results not provided). The patient was diagnosed with benign paroxysmal positional vertigo (BPPV) and was treated with 0.9% sodium chloride (NaCl) (normal saline) and Meclizine (meclozine). At the time of this report, the patient was still experiencing extreme dizziness and vertigo. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from faintness, and out of character decision making on APR-2021, and flu like symptoms on 09-APR-2021, and had not recovered from benign paroxysmal positional vertigo. This report was serious (Hospitalization Caused / Prolonged, and Other Medically Important Condition).; Sender's Comments: 20210441536-covid-19 vaccine ad26.cov2.s-Benign paroxysmal positional vertigo, Faintness. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Influenza like illness, Metabolic function test, Pain, Pyrexia, Vertigo
Clinical narrative: BENIGN PAROXYSMAL POSITIONAL VERTIGO; OUT OF CHARACTER DECISION MAKING; FAINTNESS; FLU LIKE SYMPTOMS; This spontaneous report received from a patient concerned a 27 year old female. The patient's height, and weight were not reported. The patient never experienced a reaction to any other vaccine in past. the patient had no past medical issues. The patient had never experienced vertigo or dizziness and had no recent changes to diet, activities, or lifestyle. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on left arm on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021 (upon receiving the vaccine), the patient experienced flu-like symptoms, a high fever and body aches for the first 24 hours. On 13-APR-2021, the patient began to experience severe dizziness, vertigo, faintness, mild headaches, blurred vision, and out of character decision making. On 16-APR-2021 at 15:15, the patient was hospitalized for severe dizziness and blurred vision where he had blood human chorionic gonadotrophin, complete blood count (CBC), comprehensive metabolic panel, electrocardiogram, blood magnesium level and urinalysis (results not provided). The patient was diagnosed with benign paroxysmal positional vertigo (BPPV) and was treated with 0.9% sodium chloride (NaCl) (normal saline) and Meclizine (meclozine). At the time of this report, the patient was still experiencing extreme dizziness and vertigo. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from faintness, and out of character decision making on APR-2021, and flu like symptoms on 09-APR-2021, and had not recovered from benign paroxysmal positional vertigo. This report was serious (Hospitalization Caused / Prolonged, and Other Medically Important Condition).; Sender's Comments: 20210441536-covid-19 vaccine ad26.cov2.s-Benign paroxysmal positional vertigo, Faintness. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vertigo positional, Vision blurred
Clinical narrative: BENIGN PAROXYSMAL POSITIONAL VERTIGO; OUT OF CHARACTER DECISION MAKING; FAINTNESS; FLU LIKE SYMPTOMS; This spontaneous report received from a patient concerned a 27 year old female. The patient's height, and weight were not reported. The patient never experienced a reaction to any other vaccine in past. the patient had no past medical issues. The patient had never experienced vertigo or dizziness and had no recent changes to diet, activities, or lifestyle. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on left arm on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021 (upon receiving the vaccine), the patient experienced flu-like symptoms, a high fever and body aches for the first 24 hours. On 13-APR-2021, the patient began to experience severe dizziness, vertigo, faintness, mild headaches, blurred vision, and out of character decision making. On 16-APR-2021 at 15:15, the patient was hospitalized for severe dizziness and blurred vision where he had blood human chorionic gonadotrophin, complete blood count (CBC), comprehensive metabolic panel, electrocardiogram, blood magnesium level and urinalysis (results not provided). The patient was diagnosed with benign paroxysmal positional vertigo (BPPV) and was treated with 0.9% sodium chloride (NaCl) (normal saline) and Meclizine (meclozine). At the time of this report, the patient was still experiencing extreme dizziness and vertigo. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from faintness, and out of character decision making on APR-2021, and flu like symptoms on 09-APR-2021, and had not recovered from benign paroxysmal positional vertigo. This report was serious (Hospitalization Caused / Prolonged, and Other Medically Important Condition).; Sender's Comments: 20210441536-covid-19 vaccine ad26.cov2.s-Benign paroxysmal positional vertigo, Faintness. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abnormal behaviour, Blood magnesium, Electrocardiogram, Full blood count, Human chorionic gonadotropin
Clinical narrative: BENIGN PAROXYSMAL POSITIONAL VERTIGO; OUT OF CHARACTER DECISION MAKING; FAINTNESS; FLU LIKE SYMPTOMS; This spontaneous report received from a patient concerned a 27 year old female. The patient's height, and weight were not reported. The patient never experienced a reaction to any other vaccine in past. the patient had no past medical issues. The patient had never experienced vertigo or dizziness and had no recent changes to diet, activities, or lifestyle. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on left arm on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021 (upon receiving the vaccine), the patient experienced flu-like symptoms, a high fever and body aches for the first 24 hours. On 13-APR-2021, the patient began to experience severe dizziness, vertigo, faintness, mild headaches, blurred vision, and out of character decision making. On 16-APR-2021 at 15:15, the patient was hospitalized for severe dizziness and blurred vision where he had blood human chorionic gonadotrophin, complete blood count (CBC), comprehensive metabolic panel, electrocardiogram, blood magnesium level and urinalysis (results not provided). The patient was diagnosed with benign paroxysmal positional vertigo (BPPV) and was treated with 0.9% sodium chloride (NaCl) (normal saline) and Meclizine (meclozine). At the time of this report, the patient was still experiencing extreme dizziness and vertigo. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from faintness, and out of character decision making on APR-2021, and flu like symptoms on 09-APR-2021, and had not recovered from benign paroxysmal positional vertigo. This report was serious (Hospitalization Caused / Prolonged, and Other Medically Important Condition).; Sender's Comments: 20210441536-covid-19 vaccine ad26.cov2.s-Benign paroxysmal positional vertigo, Faintness. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Influenza like illness, Metabolic function test, Syncope, Urine analysis, Vertigo positional
Clinical narrative: BENIGN PAROXYSMAL POSITIONAL VERTIGO; OUT OF CHARACTER DECISION MAKING; FAINTNESS; FLU LIKE SYMPTOMS; This spontaneous report received from a patient concerned a 27 year old female. The patient's height, and weight were not reported. The patient never experienced a reaction to any other vaccine in past. the patient had no past medical issues. The patient had never experienced vertigo or dizziness and had no recent changes to diet, activities, or lifestyle. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on left arm on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021 (upon receiving the vaccine), the patient experienced flu-like symptoms, a high fever and body aches for the first 24 hours. On 13-APR-2021, the patient began to experience severe dizziness, vertigo, faintness, mild headaches, blurred vision, and out of character decision making. On 16-APR-2021 at 15:15, the patient was hospitalized for severe dizziness and blurred vision where he had blood human chorionic gonadotrophin, complete blood count (CBC), comprehensive metabolic panel, electrocardiogram, blood magnesium level and urinalysis (results not provided). The patient was diagnosed with benign paroxysmal positional vertigo (BPPV) and was treated with 0.9% sodium chloride (NaCl) (normal saline) and Meclizine (meclozine). At the time of this report, the patient was still experiencing extreme dizziness and vertigo. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from faintness, and out of character decision making on APR-2021, and flu like symptoms on 09-APR-2021, and had not recovered from benign paroxysmal positional vertigo. This report was serious (Hospitalization Caused / Prolonged, and Other Medically Important Condition).; Sender's Comments: 20210441536-covid-19 vaccine ad26.cov2.s-Benign paroxysmal positional vertigo, Faintness. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Blood glucose abnormal, Fatigue, Headache, Hypersensitivity
Clinical narrative: Patient presented to the ER following a covid vaccine 4 days prior. Patient was seen with complaints of cough, shortness of breath, chills, nausea, sore throat and fever.
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Oropharyngeal pain, Pain, Rash
Clinical narrative: Patient presented to the ER following a covid vaccine 4 days prior. Patient was seen with complaints of cough, shortness of breath, chills, nausea, sore throat and fever.
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest X-ray, Chills, Cough, Dyspnoea, Electrocardiogram
Clinical narrative: Patient presented to the ER following a covid vaccine 4 days prior. Patient was seen with complaints of cough, shortness of breath, chills, nausea, sore throat and fever.
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fibrin D dimer, Nausea, Oropharyngeal pain, Pyrexia
Clinical narrative: Patient presented to the ER following a covid vaccine 4 days prior. Patient was seen with complaints of cough, shortness of breath, chills, nausea, sore throat and fever.
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Blood test, Confusional state, Fatigue, Joint swelling
Clinical narrative: Venous thrombosis of proximal greater saphenous vein
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Peripheral swelling, Ultrasound scan abnormal
Clinical narrative: Venous thrombosis of proximal greater saphenous vein
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fibrin D dimer increased, Ultrasound scan, Venous thrombosis limb
Clinical narrative: Venous thrombosis of proximal greater saphenous vein
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Erythema, Laboratory test, Pain in extremity, Peripheral swelling, Ultrasound Doppler
Clinical narrative: DVT blood clot formed in left leg, intense pain started almost 14 days after vaccine. No history of any health concerns with blood clots, healthy 35 year old male who works out and diets. No long drives or sedentary lifestyle.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: X-ray
Clinical narrative: DVT blood clot formed in left leg, intense pain started almost 14 days after vaccine. No history of any health concerns with blood clots, healthy 35 year old male who works out and diets. No long drives or sedentary lifestyle.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood test, Deep vein thrombosis, Pain, Thrombosis, Ultrasound scan
Clinical narrative: DVT blood clot formed in left leg, intense pain started almost 14 days after vaccine. No history of any health concerns with blood clots, healthy 35 year old male who works out and diets. No long drives or sedentary lifestyle.
Age: 35.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Urine analysis, X-ray
Clinical narrative: DVT blood clot formed in left leg, intense pain started almost 14 days after vaccine. No history of any health concerns with blood clots, healthy 35 year old male who works out and diets. No long drives or sedentary lifestyle.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Migraine
Clinical narrative: Shortly after receiving 2nd dose, client started to experience a constant and severe headache accompanied with a swollen face. Client has seen her PCP and was given a shot for tension headaches - did not relieve pain. Client went to ER 4/27/2021 and was treated with pain shots - little relief from pain. Client is still experiencing headaches and swelling. Client has an upcoming appointment with a neurologist in May.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fibrin D dimer normal, Headache, Laboratory test normal, Liver function test normal, Swelling face
Clinical narrative: Shortly after receiving 2nd dose, client started to experience a constant and severe headache accompanied with a swollen face. Client has seen her PCP and was given a shot for tension headaches - did not relieve pain. Client went to ER 4/27/2021 and was treated with pain shots - little relief from pain. Client is still experiencing headaches and swelling. Client has an upcoming appointment with a neurologist in May.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tension headache, Urine analysis
Clinical narrative: Shortly after receiving 2nd dose, client started to experience a constant and severe headache accompanied with a swollen face. Client has seen her PCP and was given a shot for tension headaches - did not relieve pain. Client went to ER 4/27/2021 and was treated with pain shots - little relief from pain. Client is still experiencing headaches and swelling. Client has an upcoming appointment with a neurologist in May.
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Swollen tongue
Clinical narrative: swelling of face, facial numbness
Age: 42.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia, Swelling face
Clinical narrative: swelling of face, facial numbness
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Guillain-Barre syndrome, Lumbar puncture
Clinical narrative: Guillain Barre Syndrome final diagnosis. 4 weeks in hospital first week after vaccine severe  pain in legs, back and shoulders. Took 7  days to diagnose. During that time  he was waiting  diagnosis he had several MRI?s Ct scans etc. Heart cath requiring a stint. Delirium and Hallucinations . Now he is totally dependent on everyone to take care of  him. Paralyzed from neck down.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Back pain, Catheterisation cardiac abnormal, Computerised tomogram, Coronary arterial stent insertion
Clinical narrative: Guillain Barre Syndrome final diagnosis. 4 weeks in hospital first week after vaccine severe  pain in legs, back and shoulders. Took 7  days to diagnose. During that time  he was waiting  diagnosis he had several MRI?s Ct scans etc. Heart cath requiring a stint. Delirium and Hallucinations . Now he is totally dependent on everyone to take care of  him. Paralyzed from neck down.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Delirium, Guillain-Barre syndrome, Hallucination, Impaired self-care, Magnetic resonance imaging
Clinical narrative: Guillain Barre Syndrome final diagnosis. 4 weeks in hospital first week after vaccine severe  pain in legs, back and shoulders. Took 7  days to diagnose. During that time  he was waiting  diagnosis he had several MRI?s Ct scans etc. Heart cath requiring a stint. Delirium and Hallucinations . Now he is totally dependent on everyone to take care of  him. Paralyzed from neck down.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Paralysis
Clinical narrative: Guillain Barre Syndrome final diagnosis. 4 weeks in hospital first week after vaccine severe  pain in legs, back and shoulders. Took 7  days to diagnose. During that time  he was waiting  diagnosis he had several MRI?s Ct scans etc. Heart cath requiring a stint. Delirium and Hallucinations . Now he is totally dependent on everyone to take care of  him. Paralyzed from neck down.